Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth by Kondo, Keiichi et al.
Inhibition of HIF2a Is Sufficient to Suppress
pVHL-Defective Tumor Growth
Keiichi Kondo
1, William Y. Kim
1, Mirna Lechpammer
2, William G. Kaelin, Jr.
1,3*
1 Department of Adult Oncology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of
America, 2 Department of Pathology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of
America, 3 Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America
Biallelic inactivation of the von Hippel–Lindau tumor suppressor gene (VHL) is linked to the development of hereditary
(VHL-associated) and sporadic clear-cell renal carcinomas as well as other abnormalities. The VHL gene product, pVHL,
is part of an E3 ubiquitin ligase complex that targets the a subunits of the heterodimeric transcription factor HIF
(hypoxia-inducible factor) for degradation in the presence of oxygen. Here we report that a HIF2a variant lacking both
of its two prolyl hydroxylation/pVHL-binding sites prevents tumor inhibition by pVHL in a DNA-binding dependent
manner. Conversely, downregulation of HIF2a with short hairpin RNAs is sufficient to suppress tumor formation by
pVHL-defective renal carcinoma cells. These results establish that tumor suppression by pVHL is linked to regulation of
HIF target genes.
Introduction
von Hippel–Lindau (VHL) disease is caused by hetero-
zygous germline inactivation of the VHL tumor suppressor
gene, which resides on chromosome 3p25 (Kaelin 2002). The
cardinal feature of this hereditary cancer syndrome is the
development of multiple vascular tumors, called hemangio-
blastomas, in the central nervous system and retina, as well as
an increased risk of clear-cell carcinoma of the kidney and
pheochromocytoma. Tumor development in VHL disease is
linked to somatic inactivation or loss of the remaining wild-
type VHL allele, leading to loss of the wild-type VHL gene
product, pVHL. In the kidney, this event occurs very early, as
it has been documented in epithelial cells lining premalig-
nant renal cysts (Zhuang et al. 1995; Lubensky et al. 1996;
Mandriota et al. 2002). Consistent with Knudson’s two-hit
model, somatic VHL mutations are also common in sporadic
clear-cell renal carcinomas and hemangioblastomas. Con-
versely, restoration of pVHL function is sufﬁcient to suppress
tumor formation by pVHL-defective renal carcinoma cells in
vivo (Iliopoulos et al. 1995; Gnarra et al. 1996; Schoenfeld et
al. 1998).
pVHL is the substrate recognition module of an E3
ubiquitin ligase complex that contains elongin B, elongin C,
Cul2, and Rbx1 (also called ROC1 or Hrt1) (Kaelin 2002). This
complex targets the a subunits of the heterodimeric tran-
scription factor HIF (hypoxia-inducible factor) for polyubiq-
uitination and hence proteasomal degradation. There are
three human HIFa proteins (HIF1a, HIF2a, and HIF3a).
Enzymatic hydroxylation of conserved prolyl residues within
these proteins by members of the egg-laying-defective nine
(EGLN) family is required for their recognition by pVHL
(Kaelin 2002). This posttranslational modiﬁcation is inher-
ently oxygen-dependent. Accordingly, HIFa subunits are
normally unstable in the presence of oxygen, but are
stabilized under low-oxygen (hypoxic) conditions. In contrast,
cells lacking wild-type pVHL fail to degrade HIFa subunits in
the presence of oxygen, and thus hypoxia-inducible gene
products are constitutively overproduced. Among these
proteins are vascular endothelial growth factor (VEGF) and
platelet-derived growth factor B, implicated in angiogenesis;
phosphoglycerate kinase and glucose transporter 1 (GLUT1),
involved in glucose uptake and metabolism; and transforming
growth factor a (TGFa), which can establish a mitogenic
autocrine loop with the epidermal growth factor (EGF)
receptor (EGFR) (Iliopoulos et al. 1996; Knebelmann et al.
1998; Maxwell et al. 1999; de Paulsen et al. 2001).
Tumor-derived pVHL mutants are typically defective with
respect to HIF polyubiquitination in vivo, and the HIF target
genes cited above are implicated in tumorigenesis. Thus,
correlative data and biological plausibility support a role for
HIF in pVHL-defective tumor formation. Nonetheless,
emerging genotype–phenotype correlations in VHL disease
suggest that pVHL has multiple functions. For example,
pVHL mutants associated with a low risk (type 2A VHL
disease) and high risk (type 2B disease) of renal cell carcinoma
are similarly defective with respect to HIF regulation
(Clifford et al. 2001; Hoffman et al. 2001). Interestingly,
individuals with Chuvash polycythemia are homozygous for a
hypomorphic VHL allele that is quantitatively defective with
respect to HIF regulation, which leads to overproduction of
erythropoietin in vivo but not tumor formation (Ang et al.
2002). Moreover, forced activation of HIF target genes has
not led to tumor formation in the animal models tested so far
(Vincent et al. 2000; Elson et al. 2001; Rebar et al. 2002).
Conversely, some pVHL mutants that retain the ability to
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PLoS BIOLOGYregulate HIF are linked to familial pheochromocytoma (type
2C VHL disease) (Clifford et al. 2001; Hoffman et al. 2001).
Collectively, these ﬁndings suggest that tumor formation
following pVHL inactivation reﬂects the loss of multiple
pVHL functions in a context-dependent manner.
In this report we provide data that strengthen our earlier
conclusion that inhibition of HIF2a is necessary for pVHL-
dependent suppression of renal carcinoma tumor formation
in vivo (Kondo et al. 2002). Moreover, we provide evidence
that inhibition of HIF2a is likewise sufﬁcient to suppress
tumor formation by VHL( / ) renal carcinoma cells in vivo.
Collectively, these results indicate that HIF2a is a critical
downstream target of pVHL with respect to suppression of
renal carcinogenesis.
Results and Discussion
Inhibition of HIF2a Target Genes Is Necessary for Tumor
Suppression by pVHL
Hydroxylation of HIF1a Pro564 or HIF2a Pro531 generates
a pVHL-binding site (Ivan et al. 2001; Jaakkola et al. 2001; Yu
et al. 2001). We previously showed that a HIF2a variant in
which Pro531 was replaced by alanine (HIF2a P531A) escaped
recognition by pVHL and induced the expression of HIF
target genes in vivo (Kondo et al. 2002). Moreover, HIF2a
P531A abrogated pVHL-dependent tumor suppression in
vivo, implying that HIF is functionally downstream of pVHL
and that inhibition of HIF is necessary for tumor suppression
by pVHL (Kondo et al. 2002). Shortly thereafter, it was shown
that hydroxylation of HIF1a Pro404 (corresponding to HIF2a
Pro405) creates a second potential pVHL-binding site within
HIF1a (Masson et al. 2001). Although we could not detect a
physical interaction between pVHL and HIF2a P531A
(Kondo et al. 2002), the identiﬁcation of a second potential
pVHL-binding site left open the possibility that the biological
effects of HIF2a P531A were due, at least partly, to
perturbation of pVHL function as a result of direct binding.
If true, this would undermine the conclusions described
above. Moreover, we had not established whether the
biological effects of HIF2a P531A required that it bind to
DNA, as would be expected if its oncogenic effects were due
to transcriptional activation of speciﬁc hypoxia-inducible
promoters. To this end, we repeated our earlier experiments
using retroviral vectors encoding HIF2a P405A;P531A or
HIF2a P405A;P531A;bHLH*. The latter contains a ﬁve amino
acid substitution within the HIF2a basic helix–loop–helix
(bHLH) domain that leads to loss of DNA-binding capability
(Kondo et al. 2002).
786-O renal carcinoma cells lack wild-type pVHL and
overproduce HIF2a (Iliopoulos et al. 1995; Maxwell et al.
1999). HIF1a is not detectable in these cells (Maxwell et al.
1999). Reintroduction of wild-type pVHL into 786-O cells by
stable transfection does not affect cell growth in vitro under
standard serum-rich growth conditions, but leads to down-
regulation of HIF2a protein levels, suppression of hypoxia-
inducible gene expression, and impaired tumorigenesis in
vivo (Iliopoulos et al. 1995, 1996; Gnarra et al. 1996;
Schoenfeld et al. 1998; Maxwell et al. 1999; Davidowitz et al.
2001). A 786-O subclone stably transfected to produce wild-
type pVHL (WT8) (Iliopoulos et al. 1995) was infected with a
retrovirus encoding HIF2a P405A;P531A or HIF2a
P405A;P531A;bHLH* and grown under hypoxic (1% oxygen)
or normoxic (21% oxygen) conditions. As expected, HIF2a
was only detectable under hypoxic conditions in WT8 cells
and in WT8 cells infected with an empty retrovirus (Figure
1A). In contrast, HIF2a was readily detectable under both
hypoxic and normoxic conditions in WT8 cells infected to
produce either of the two HIF2a P405A;P531A variants.
Indeed, the levels of HIF2a present in these cells approxi-
mated those seen in a 786-O subclone (PRC3) (Iliopoulos et al.
1995) that, unlike WT8 cells, was stably transfected with an
empty expression plasmid and hence still lacks wild-type
pVHL.
Neither HIF2a P405A;P531A nor HIF2a P405A;P531A;
bHLH* affected the proliferation of WT8 cells in vitro under
standard cell culture conditions (Figure 1B). In contrast, but
in keeping with our earlier results with HIF2a P531A (Kondo
et al. 2002), HIF2a P405A;P531A restored the ability of WT8
cells to form large tumors in vivo in nude mouse xenograft
assays (Figure 1C). HIF2a P405A;P531A;bHLH* did not
promote tumor formation by WT8 cells, implying that tumor
Figure 1. HIF2a Overrides Tumor Suppression by pVHL
(A) 786-O subclones that were transfected to produce wild-type
pVHL (WT8) or with an empty plasmid (PRC3) cells, as well as WT8
cells infected with an empty retrovirus (Empty) or retroviruses
encoding the indicated HIF2a variants [ (P!A)
2 ¼ P405A;P531A and
* ¼ bHLH mutation] were grown in the presence of 21% or 1%
oxygen and immunoblotted (IB) with the indicated antibodies.
(B) In vitro proliferation of WT8 cells infected with the indicated
retroviruses.
(C) Tumor weights approximately 9 wk after subcutaneous implanta-
tion of WT8 cells infected with the indicated retroviruses in nude
mice. Number of tumors analyzed is shown in parentheses. Error bars
¼ one standard error.
DOI: 10.1371/journal/pbio.0000083.g001
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HIF2a Required by pVHL-Defective Tumorspromotion by HIF2a P405A;P531A is linked to its ability to
act as a sequence-speciﬁc DNA-binding transcriptional
regulator. These results, together with our earlier ﬁndings,
indicate that inhibition of HIF2a is necessary for tumor
suppression by pVHL.
Loss of HIF2a Is Sufficient to Suppress pVHL-Defective
Tumor Growth In Vivo
To ask whether inhibition of HIF2a is likewise sufﬁcient for
tumor suppression by pVHL, we set out to inhibit HIF2a in
VHL( / ) renal carcinoma cells using short hairpin RNAs
(shRNA). We tested ﬁve HIF2a shRNAs based on 19mer
sequences that are unique to HIF2a according to GenBank.
Two such shRNAs (#2 and #3) decreased HIF2a protein levels,
as determined by anti-HIF2a immunoblot analysis and by
diminished activity of a cotransfected HRE–luciferase re-
porter plasmid, when transiently introduced into 786-O cells
(data not shown). Infection of 786-O cells with retroviruses
encoding shRNA #2 or #3, but not the parental retrovirus, led
to decreased steady-state levels of HIF2a protein as well as
decreased levels of GLUT1, which is encoded by a HIF-
responsive gene (Figure 2A). Downregulation of HIF2a did
not affect cell growth in vitro, but was sufﬁcient to impair
tumor growth in vivo (Figure 2B–2D). The former observation
is consistent with the ﬁnding that pVHL does not inhibit cell
proliferation under standard cell culture conditions and
argues against the idea that the latter was due to nonspeciﬁc
toxicity. Moreover, these in vivo effects could be prevented by
coadministration of a retrovirus encoding an HIF2a mRNA
with silent third-base mutations within the shRNA recogni-
tion site (Figure 3) and were not observed with retroviruses
encoding a scrambled HIF2a shRNA or luciferase shRNA
(data not shown). Thus, tumor suppression by the HIF2a
shRNA was unlikely to reﬂect a spurious interaction with an
unintended target.
To ask whether these ﬁndings could be extended to other
VHL( / ) renal carcinoma cell lines, we repeated these
Figure 2. Downregulation of HIF2a Is Sufficient to Suppress Tumor
Growth by pVHL-Defective Renal Carcinoma Cells
(A) Parental 786-O cells (VHL[ / ]) and 786-O cells infected with an
empty retrovirus (Empty) or retroviruses encoding HIF2a shRNAs
(sequence #2 or #3) were grown in the presence of 21% or 1% oxygen
and immunoblotted (IB) with the indicated antibodies.
(B) In vitro proliferation of 786-O cells infected with the indicated
retroviruses.
(C) Tumor weights approximately 9 wk after subcutaneous implanta-
tion of 786-O cells infected with the indicated retroviruses in nude
mice. Number of tumors analyzed is shown in parentheses. Error bars
¼ one standard error.
(D) Representative photograph of nude mouse 9 wk after subcuta-
neous injection of 786-O cells in left (upper) ﬂank and 786-O cells
infected with HIF2a shRNA (#3) retrovirus on right (lower) ﬂank.
DOI: 10.1371/journal/pbio.0000083.g002
Figure 3. Effect of HIF2a shRNA Is Specifically Due to Downregulation of
HIF2a
(A) Parental 786-O cells (VHL[ / ]) and 786-O cells stably producing
HIF2a shRNA #3 that were coinfected with an empty retrovirus
(Empty) or a retrovirus encoding a HIF2a mRNA with three silent
mutations in the #3 recognition site (MT*) were grown in the
presence of 21% or 1% oxygen and immunoblotted (IB) with the
indicated antibodies.
(B) In vitro proliferation of 786-O HIF2a shRNA #3 cells infected
with the indicated retroviruses.
(C) Tumor weights approximately 9 wk after subcutaneous implanta-
tion of 786-O HIF2a shRNA cells infected with the indicated
retroviruses in nude mice. Number of tumors analyzed is shown in
parentheses. Error bars ¼ one standard error.
(D) Representative photograph of nude mouse 9 wk after subcuta-
neous injection of 786-O HIF2a shRNA #3 cells in left (upper) ﬂank
and 786-O HIF2a shRNA #3 cells infected with retrovirus encoding
HIF2a MT* mRNA on right (lower) ﬂank.
DOI: 10.1371/journal/pbio.0000083.g003
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HIF2a Required by pVHL-Defective Tumorsexperiments in A498 VHL( / ) renal carcinoma cells. Tumor
formation by these cells in nude mice is diminished following
restoration of pVHL function (Lonergan et al. 1998). In
keeping with the results obtained with 786-O cells, down-
modulation of HIF2a levels with shRNA did not affect A498
cell growth in vitro (data not shown), but dramatically
inhibited tumor growth in vivo (Figure 4A). It is noteworthy
that both 786-O cells and A498 cells produce HIF2a and not
HIF1a (Maxwell et al. 1999). It will be important in the future
to ask whether disruption of HIF2a is sufﬁcient to suppress
tumor formation by pVHL-defective cells that produce both
HIFa paralogs. In this regard, studies of renal precursor
lesions in VHL patients suggest that HIF2a is more oncogenic
than HIF1a (Mandriota et al. 2002). It is tempting to speculate
that loss of HIF1a expression in some pVHL-defective renal
carcinoma cells confers a selective advantage in vivo, perhaps
related to the ability of HIF1a to induce apoptosis in some
settings (Carmeliet et al. 1998).
Several histological renal carcinoma variants have been
recognized, including clear-cell carcinoma and papillary
(chromophil) carcinoma. VHL mutations are common in the
former, but not in the latter (Gnarra et al. 1994; Takahashi et
al. 2002). Interestingly, the small A498 tumors that did form
in the presence of HIF2a shRNA consisted of malignant cells
forming tubulopapillary structures, corresponding to papil-
lary (chromophil) renal carcinoma histology, whereas the
empty vector tumors consisted primarily of sheets of clear
cells, as would be seen in typical clear-cell renal carcinoma,
with interspersed areas displaying papillary features (Figure
4B). This suggests that dysregulation of HIF2a is causally
linked to the clear-cell pattern and is consistent with the tight
linkage between VHL mutations and this renal carcinoma
subtype.
Most of the work performed so far with respect to the
oncogenic effects of HIF has focused exclusively on HIF1a,
where both prooncogenic and antioncogenic effects have
been reported (Maxwell et al. 1997; Carmeliet et al. 1998;
Ryan et al. 1998, 2000; Hopﬂ et al. 2002). Likewise, loss of
pVHL is prooncogenic in a restricted subset of human tissues
(Kaelin 2002). In the mouse, loss of pVHL promotes
hemangioma development in the liver, but inhibits tumor
formation by embryonic stem cells (Haase et al. 2001; Mack et
al. 2003). These observations conform to the emerging
paradigm that the same mutation can be either prooncogenic
or antioncogenic, depending on the molecular and cellular
context. Therefore, one must be cautious in extrapolating our
ﬁndings beyond human clear-cell renal carcinomas.
Loss of pVHL in the human kidney gives rise to
premaligant renal cysts (Zhuang et al. 1995; Lubensky et al.
1996; Mandriota et al. 2002). It is presumed that additional
mutations at non-VHL loci are required for conversion to
frank renal cell carcinomas. It will therefore be of interest to
determine whether dysregulation of HIF is sufﬁcient to
produce renal cysts. In this regard, TGFa, which is encoded by
a HIF target gene, is a potent renal mitogen and is sufﬁcient
to induce renal cysts in the mouse (Lowden et al. 1994;
Chailler and Briere 1998; Ramp et al. 2000; de Paulsen et al.
2001). On the other hand, our data do not exclude the
possibility that the development of renal pathology following
pVHL loss in humans reﬂects a complex interplay between
dysregulated HIF2a and loss of a second pVHL function.
pVHL has been implicated in control of cell-cycle, differ-
entiation, and extracellular matrix formation, although the
extent to which these activities are due to control of HIF is
not known (Kaelin 2002). A number of non-HIF pVHL-
binding partners have, however, been reported, including
atypical protein kinase C members, VDU1, SP1, and
ﬁbronectin (Kaelin 2002).
Therapeutic Implications
Our ﬁndings strengthen the notion that inhibition of
HIF2a might be therapeutically useful in pVHL-defective
clear-cell renal carcinoma. On the other hand, sequence-
speciﬁc DNA-binding transcription factors have not proven
to be attractive drug targets to date. For this reason, it will be
important to determine which HIF2a target genes are
necessary for its oncogenic activity. Among the known HIF
targets, the abovementioned TGFa and its cognate receptor,
EGFR, are frequently overproduced in renal carcinoma and
are suspected to establish an autocrine loop (Mydlo et al.
1989; Lager et al. 1994; Knebelmann et al. 1998; de Paulsen et
al. 2001). A number of EGFR are presently in clinical trials
(Fabbro et al. 2002). Likewise, overproduction of VEGF is
common in renal cell carcinoma and likely contributes to
tumor angiogenesis in this setting (Walke et al. 1991; Brown et
al. 1993; Takahashi et al. 1994; Nicol et al. 1997; Ramp et al.
1997). Drugs directed against VEGF or its receptors are also
Figure 4. Tumor Suppression by HIF2a shRNA Is Not Restricted to a
Single Cell Line
(A) Tumor weights approximately 8 wk after subcutaneous implanta-
tion of A498 cells infected with the indicated retroviruses in nude
mice. Number of tumors analyzed is shown in parentheses. Error bars
¼ one standard error.
(B) Representative histological sections after staining with hematox-
ylin and eosin of tumors formed by A498 cells infected with the
indicated retroviruses.
DOI: 10.1371/journal/pbio.0000083.g004
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HIF2a Required by pVHL-Defective Tumorsbeing tested in humans (Fabbro et al. 2002). In a recent Phase
II study, a neutralizing VEGF antibody was shown to delay
disease progression in metastatic renal carcinoma (Yang et al.
2003) and offers hope that rational combinations of small
molecules directed against HIF targets will alter the natural
history of this disease.
Materials and Methods
Plasmids. pBABE-puro-HA-HIF2a P405A;P531A was generated by
two-step PCR. The pcDNA3.0-HA-HIF2a P531A (Kondo et al. 2002)
insert was ﬁrst ampliﬁed with primer A (59-GCGCGGATCCGCCAC-
CATGACA-39) and primer B (59-TCCTGGGGTAGCAGCCAGCTG-39)
or primer C (59-CAGCTGGCTGCTACCCCAGGA-39) and primer D
(59-GCGCCAATTGTCAGGTGGCCTGGTC-39). Aliquots of these two
PCRs were then mixed and ampliﬁed with primers A and D. The
resulting PCR product was digested with BamHI and MunI and
ligated into pBABE-puro-HA vector cut with BamHI and EcoRI. In
parallel, similar reactions were carried out with pcDNA3.0-HA-HIF2a
P531A/bHLH* (Kondo et al. 2002) as the PCR template to make
pBABE-puro HA-HIF2a P405A;P531A;bHLH* (conversion of amino
acids residues 24–29, RCRRSK to ACAASA).
Short interfering RNAs (siRNAs) corresponding to two unique
HIF2a 19mer sequences (#2, 59-GACAAGGTCTGCAAAGGGT-39 and
#3, 59-GGAGACGGAGGTGTTCTAT-39) downregulated HIF2a pro-
tein levels and HIF-dependent transcriptional activity. Synthetic
oligonucleotides spanning the #2 siRNA sequence (59-GATCCCCG-
ACAAGGTCTGCAAAGGGTTTCAAGAGAACCCTTTGCAGACCTT-
GTCTTTTTGGAAA-39 and 59-AGCTTTTCCAAAAAGACAAGGTC-
TGCAAAGGGTTCTCTTGAAACCCTTTGCAGACCTTGTCGGG-39)
or the #3 sequence (59-GATCCCCGGAGACGGAGGTGTTCTATTT-
CAAGAGAATAGAACACCTCCGTCTCCTTTTTGGAAA and 59-AG-
CTTTTCCAAAAAGGAGACGGAGGTGTTCTATTCTCTTGAAATA-
GAACACCTCCGTCTCCGGG-39) were annealed by incubation in 30
mM HEPES–KOH (pH 7.4), 100 mM potassium acetate, 30 mM
HEPES–KOH, 2 mM Mg–acetate for 4 min at 958C followed by 10 min
at 708C. The resulting duplex oligonucleotides were phosphorylated
with T4 polynucleotide kinase (Roche Molecular Biochemicals,
Mannheim, Germany) according to the manufacturer’s protocol and
ligated into pRETRO-SUPER vector (Brummelkamp et al. 2002) cut
with BglII and HindIII.
The pBABE-hygro-HA-HIF2a siRNA recognition site mutant for
#3 siRNA (59-GGAGACCGAAGTCTTCTAT-39) (called HIF2a MT)
was generated by two-step PCR. The pcDNA3.0-HA-HIF2a insert was
ﬁrst ampliﬁed was ﬁrst ampliﬁed with primer A and primer E (59-
GTCTCCTTGCTCCGCCG-39) or primer F (59-CGAAGTCTTCTAT-
GAGCTGGCCCATG-39) and primer D. Aliquots of these two PCRs
were then mixed and ampliﬁed with primers A and D. The resulting
PCR product was digested with BamHI and MunI and ligated into
pBABE-hygro-HA vector cut with BamHI and EcoRI.
All plasmids were authenticated by DNA sequencing. pGL2-VEGF
promoter plasmid was a kind gift from Dr. Deb Mukhopadhyay
(Harvard Medical School, Boston, Massachusetts, United States). pSV-
b-Gal plasmid was purchased from Promega Corporation (Madison,
Wisconsin, United States).
Cell culture. Renal carcinoma cell lines (786-O and A498) and
Phoenix cells (a generous gift of Dr. Gary Nolan, Department of
Molecular Pharmacology, Stanford University, Stanford, California,
United States) were grown in Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal clone I (Hyclone, Logan Utah, United States) in
presence of 10% CO2 at 378C. 786-O renal cell carcinoma subclones
stably transfected with either pRc/CMV empty vector (PRC3) or pRc/
CMV-HA-VHL (WT8) (Iliopoulos et al. 1995) were grown in the same
media supplemented with 1 mg/ml G418. Retrovirally infected cells
were selected and maintained in the presence of puromycin (1.5 lg/
ml for pBABE-puro retroviruses or 1.0 lg/ml for pSUPER retro-
viruses) or hygromycin 0.5 lg/ml for pBABE-hygro retrovirus.
Retroviruses. Retroviral plasmids were transfected into the
Phoenix packaging cell line using FuGene (Roche Molecular
Biochemicals) according to the manufacturer’s instructions. Tissue
culture supernatant was harvested 48 h later, passed though a 0.45-
lm ﬁlter, and added to cells in the presence of 4 lg/ml polybrene.
Immunoblot analysis. Cells were lysed in EBC lysis buffer (50 mM
Tris [pH 8.0], 120 mM NaCl, 0.5% NP-40) supplemented with
complete protease inhibitor cocktail (Roche Molecular Biochemicals).
Approximately 300 lg of cell extract per lane, as determined by the
Bradford method, was resolved by SDS–polyacrylamide gel electro-
phoresis and transferred to polyvinylidene diﬂuoride membranes
(Bio-Rad, Hercules, California, United States). After blocking in Tris-
buffered saline (TBS) with 4% nonfat milk, the membranes were
probed with anti-HA rabbit polyclonal antibody (Y-11; Santa Cruz
Biotechnology, Santa Cruz, California, United States), anti-HIF2a
mouse monoclonal antibody (NB100–132; Novus Biologicals, Little-
ton, Colorado, United States), anti-GLUT1 rabbit polyclonal antibody
(GT11-A; Alpha Diagnostic, San Antonio, Texas, United States), or
anti-actin goat polyclonal antibody (sc-1615; Santa Cruz Biotechnol-
ogy) diluted in TBS with 4% bovine serum albumin. Bound antibody
was detected with horseradish peroxidase-conjugated goat anti-rabbit
IgG, goat anti-mouse IgG, or rabbit anti-goat IgG (Pierce, Rockford,
Illinois, United States) and SuperSignal West Pico chemiluminescent
substrate (Pierce) according to the manufacturer’s instructions.
In vitro proliferation assays. Approximately 5,000 cells were plated
per well in 6-well plates and grown under the cell culture conditions
described above. At various timepoints thereafter, cells were released
by trypsinization, resuspended in phosphate-buffered saline (PBS),
and stained with trypan blue. Viable cells, as determined by trypan
blue exclusion, were counted using a hemocytometer.
Nude mouse xenograft assays. Nude mouse xenograft assays were
performed as described elsewhere (Iliopoulos et al. 1995; Kondo et al.
2002). In brief, cells were released by trypsinization and resuspended
in PBS. Viable cells (10
7), as determined by trypan blue staining, were
injected subcutaneously into the ﬂanks of nude mice. Both ﬂanks were
used for each mouse. The animals were sacriﬁced 8–10 wk after
injection. Autopsy was performed by animal care technicians who
were unaware of the HIF status of the tumors. Tumors were weighed,
cut in half, and ﬁxed in either formalin or frozen in optimal cutting
temperature compound.
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